InVivo Therapeutics Holdings Corp (NVIVQ)

[Pemmanuel]

$NVIV almost always rises through May, June and July. Worth some buys now and more if the patient enrollments and conversions accelerate. In other years and on less cash and accomplishments this has skyrocketed through this time period. So I recommend as a buy in that short term as well as long, since FDA approval is expected in 2018. InVivo is further along than it has ever been in its entire existence and much closer to the prize than in July 2013 when it exceeded $480MM MC. There is no other treatment that restores motor and sensory to this degree after a spinal injury. The best providers will want to grab hold and have the new standard of care. Anyone left will be guilted into it or be left behind.